![Barbara Klencke](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 890 585 $ au 31/07/2026
Barbara J.
Klencke is currently an Independent Director at Xencor, Inc. since 2023, Immune-Onc Therapeutics, Inc. since 2022, and TScan Therapeutics, Inc. since 2023.
Dr. Klencke is also set to be Chief Medical Officer at ALX Oncology Holdings, Inc. starting in 2025.
Former roles include Medical Director at Chiron Corp.
from 2002 to 2003, Group Medical Director-Product Development at Genentech, Inc. from 2003 to 2011, Independent Director at Lexent Bio, Inc. from 2017 to 2020, Independent Director at eFFECTOR Therapeutics, Inc. from 2021 to 2024, Senior Vice President-Global Development at Onyx Pharmaceuticals, Inc. from 2011 to 2015, Chief Medical & Development Officer at Sierra Oncology, Inc. from 2015 to 2022, and Assistant Professor-Medicine in Oncology at the University of California from 1995 to 2002.
Education includes undergraduate studies at Indiana University and a doctorate from the University of California, Davis.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
XENCOR, INC. 0,04% | 16/06/2026 | 29 974 ( 0,04% ) | 605 775 $ | 31/07/2026 |
| 16/04/2026 | 120 000 ( 0,09% ) | 232 800 $ | 31/07/2026 | |
| 20/05/2026 | 70 000 ( 0,11% ) | 52 010 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| TSCAN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 06/04/2023 |
| XENCOR, INC. | Directeur/Membre du Conseil | 15/09/2023 |
| ALX ONCOLOGY HOLDINGS INC. | Directeur Technique/Scientifique/R&D | 17/09/2025 |
Immune-Onc Therapeutics, Inc.
 Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Directeur/Membre du Conseil | 08/11/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
| EFFECTOR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 21/06/2024 |
| SIERRA ONCOLOGY, INC. | Directeur Technique/Scientifique/R&D | 01/07/2022 |
Lexent Bio, Inc.
 Lexent Bio, Inc. Financial ConglomeratesFinance Develops novel liquid biopsy technologies to manage cancer | Directeur/Membre du Conseil | 01/01/2020 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01/06/2015 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/01/2011 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 13 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
Sierra Oncology, Inc.
 Sierra Oncology, Inc. BiotechnologyHealth Technology Develops novel therapeutic approaches for cancer and other diseases | Health Technology |
Xencor, Inc.
 Xencor, Inc. BiotechnologyHealth Technology Develops therapeutics to treat autoimmune and allergic diseases, cancer and other conditions | Health Technology |
Indiana University
 Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Davis
 University of California, Davis Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California
 University of California Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Lexent Bio, Inc.
Lexent Bio, Inc. Financial ConglomeratesFinance Develops novel liquid biopsy technologies to manage cancer | Finance |
TScan Therapeutics, Inc.
 TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
ALX Oncology Holdings, Inc.
 ALX Oncology Holdings, Inc. BiotechnologyHealth Technology Operates as clinical stage immuno-oncology company, which develops therapies for cancer | Health Technology |
eFFECTOR Therapeutics, Inc.
 eFFECTOR Therapeutics, Inc. BiotechnologyHealth Technology Operates as a oncology company which develops therapies for cancer | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
